Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 18 Diseases   32 Trials   32 Trials   839 News 


«12345678910111213...1516»
  • ||||||||||  Painful skin lesions after starting subcutaneous immunoglobulin replacement (Exhibit Hall (Upper Concourse); Monitor 03) -  Oct 10, 2022 - Abstract #ACAAI2022ACAAI_866;    
    Case Description Patient is on multiple immunosuppressants including ustekinumab, canakinumab, and leflunomide managed by Rheumatology...Past immune evaluation showed normal IgG and appropriate response to Pneumovax two years ago...Additionally, the patient also had a few ear infections; thus, A/I currently trialing Cuvitru at IgG replacement dosing (∼500 mg/kg)...In contrast, local reactions with swelling, pain, and bruising on SCIg infusion sites have been well reported. To our knowledge, systemic dermatological adverse reactions due to SCIg have not been reported in the past.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Retrospective data, Journal:  Pneumococcal vaccination coverage in individuals (16-59 years) with a newly diagnosed risk condition in Germany. (Pubmed Central) -  Oct 6, 2022   
    Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16-59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16-59 years of age developing conditions with higher susceptibility to pneumococcal infection.
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Journal:  Characterization of High Molecular Weight Pneumococcal Conjugate by SEC-MALS and AF4-MALS. (Pubmed Central) -  Sep 24, 2022   
    In the 1980s, PNEUMOVAX 23 were introduced as the first pneumococcal polysaccharide vaccines (PPSV)...To understand and characterize these high molecular weight (Mw) polysaccharide protein conjugates, we employed the multi-angle light scattering (MALS) technique coupled with size-exclusion chromatography (SEC) separation and asymmetrical flow field flow fractionation (AF4). MALS analysis of MVCs from the two orthogonal separation mechanisms helps shed light on the heterogeneity in conformation and aggregation states of each conjugate.
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Journal:  Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. (Pubmed Central) -  Sep 20, 2022   
    The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S. children, and the recommendations vary by age group and risk group (1,2)...ACIP employed the Evidence to Recommendation (EtR) Framework,* using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to guide its deliberations regarding use of these vaccines. Risk-based recommendations on use of PPSV23 for persons aged 2-18 years with certain underlying medical conditions that increase the risk for pneumococcal disease have not changed.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
    Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1916;    
    A gap exists with respect to vaccination for HPV, Prevnar13, Shingrix®, the COVID series & booster completion where uptake was lower for SLE women. Women with SLE are at higher risk for HPV infection and cervical cancer, shingles, & infection with COVID & pneumococcus.
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Trial completion date, Trial primary completion date:  MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) -  Sep 13, 2022   
    P=N/A,  N=45, Active, not recruiting, 
    Women with SLE are at higher risk for HPV infection and cervical cancer, shingles, & infection with COVID & pneumococcus. Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2024
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    AUSTRIAN SYNDROME IN A VACCINATED PATIENT: THE RARE STREPTOCOCCAL PNEUMONIAE TRIAD (Convention Center 103ABC) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3894;    
    Strep pneumoniae can cause pneumonia, meningitis, and endocarditis. Clinicians should have a low threshold for excluding meningitis and endocarditis in a patient with pneumococcal pneumonia.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Retrospective data, Journal, HEOR:  Comparative effectiveness of individual pneumococcal vaccines with dual pneumococcal vaccination in older United States Veterans. (Pubmed Central) -  Aug 24, 2022   
    PCV 13 was associated with a 31% decrease in the rate of pneumococcal pneumonia in comparison to PPSV 23 in older adult Veterans. Our results demonstrating clinical benefit with PCV 13 vaccination are in alignment with the latest pneumococcal vaccination guidelines that recommend routine vaccination with pneumococcal conjugate vaccines in all older adults.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Fluarix (influenza virus trivalent vaccine) / GSK, NN1213 / Novo Nordisk
    Trial completion:  Perturbing of HIV Reservoir With Immune Stimulation (clinicaltrials.gov) -  Aug 24, 2022   
    P=N/A,  N=54, Completed, 
    Our results demonstrating clinical benefit with PCV 13 vaccination are in alignment with the latest pneumococcal vaccination guidelines that recommend routine vaccination with pneumococcal conjugate vaccines in all older adults. Active, not recruiting --> Completed
  • ||||||||||  Trial primary completion date:  Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) -  Aug 8, 2022   
    P4,  N=500, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Aug 2022 --> Aug 2023
  • ||||||||||  Enrollment open:  Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) -  Aug 4, 2022   
    P4,  N=500, Recruiting, 
    Trial primary completion date: Aug 2022 --> Aug 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    Journal:  A quality improvement study: Optimizing pneumococcal vaccination rates in children with cochlear implants. (Pubmed Central) -  Jul 23, 2022   
    The value of a nurse-led dedicated immunization clinic was also demonstrated with all children (42/42, 100%) up to date with Prevenar13 and the majority (34/42, 81%) up to date with Pneumovax23 post initiation of this referral pathway. These data support the expansion of this model to other medically-at-risk paediatric groups that have been highlighted consistently to be under-vaccinated.
  • ||||||||||  Enrollment change:  Vaccine Responses in Patients With B Cell Malignancies (clinicaltrials.gov) -  Jul 12, 2022   
    P4,  N=500, Not yet recruiting, 
    Not yet recruiting --> Recruiting N=270 --> 500
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM) () -  May 13, 2022 - Abstract #EHA2022EHA_1599;    
    Aims V114 is a 15-valent pneumococcal conjugate vaccine (PCV) approved in adults, containing all 13 serotypes in Prevnar 13™ (PCV13; contains serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) as well as epidemiologically important serotypes 22F and 33F...At 12 months after HCT, participants received either PNEUMOVAX TM 23 or a fourth dose of PCV if they experienced chronic GVHD...In addition, V114 induced higher antibody responses than PCV13 for serotypes unique to V114 (22F and 33F). Study results support the use of V114 in allo-HCT recipients.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
    COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS (Poster Hall - San Diego Convention Center) -  Apr 25, 2022 - Abstract #DDW2022DDW_2990;    
    Data obtained from patients’ charts included demographics; disease characteristics including disease phenotype, number of years since diagnosis, number of IBD-related surgeries; and IBD therapy including biologics, thiopurines or methotrexate, corticosteroids, and mesalamine...Patients who received other routinely recommended vaccines (influenza, Prevnar/Pneumovax, Shingrix) were not more likely to receive COVID-19 vaccine.DiscussionAlthough majority of patients in this cohort were on an immunosuppressive medication, COVID-19 vaccination rate is only recorded to be at 57%...In this cohort, younger adults, males, and African Americans were less likely to receive COVID-19 vaccine. Healthcare providers need to recognize these potential risk factors for COVID-19 vaccine hesitancy.
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
    The uptake of vaccinations in adults with sickle cell disease receiving care at the Cambridge University Hospitals NHS Foundation Trust () -  Apr 25, 2022 - Abstract #BSH2022BSH_239;    
    We collected data on the uptake of the pneumococcal conjugate vaccine (PCV13), pneumococcal polysaccharide vaccine (PPV23 or Pneumovax) within 5 years, two doses of Meningitis B vaccine, Meningitis ACWY vaccine (MenACWY), Haemophilus influenzae type b vaccine (Hib/MenC), influenza vaccine within 1 year, hepatitis B vaccine (HepB), whether HBsAb levels have been reviewed within 1 year, HepB booster if HBsAb levels were less than 100 mIU/ml, and two doses of COVID-19 vaccine...Beyond directed patient education, more communication is needed with the primary care teams to raise awareness of which vaccinations are required for sickle cell patients. Certain vaccinations, such as MenACWY and MenB were only introduced in 2015, meaning that some general practitioners may be still unaware of their necessity in adults with sickle cell disease.
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Trial primary completion date:  MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) -  Apr 22, 2022   
    P=N/A,  N=45, Active, not recruiting, 
    Certain vaccinations, such as MenACWY and MenB were only introduced in 2015, meaning that some general practitioners may be still unaware of their necessity in adults with sickle cell disease. Trial primary completion date: Feb 2022 --> Jul 2022
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    THE IMPACT OF PNEUMOCOCCAL VACCINATION AND NASOPHARYNGEAL COLONIZATION ON THE PERFORMANCE OF A SEROTYPE-SPECIFIC URINARY ANTIGEN DETECTION ASSAY (Station 04) -  Apr 13, 2022 - Abstract #ISPPD2022ISPPD_221;    
    Methods This substudy included 301 participants from V114-017, a phase III, active comparator-controlled study...Irrespective of vaccination status, both assays demonstrated high agreement for detecting negative, but not positive, occurrences. Conclusions For some serotypes, SSUAD positivity increased transiently post-vaccination, but results did not support a positive correlation between NP/OP carriage and SSUAD results.
  • ||||||||||  SP0202 / Sanofi, SK Bio
    Trial completion:  Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. (clinicaltrials.gov) -  Apr 13, 2022   
    P2,  N=750, Completed, 
    Conclusions For some serotypes, SSUAD positivity increased transiently post-vaccination, but results did not support a positive correlation between NP/OP carriage and SSUAD results. Active, not recruiting --> Completed
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    Journal:  Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. (Pubmed Central) -  Apr 1, 2022   
    Better education surrounding vaccine recommendations is required for both health care providers and individuals with IBD given poor pneumococcal, hepatitis A virus, and influenza vaccination rates. Inadvertent administration of the rotavirus vaccine in biologic-exposed infants did not result in more adverse events, raising the possibility of safety.
  • ||||||||||  Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer
    Enrollment closed, Pneumococcal vaccines:  20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Na (clinicaltrials.gov) -  Mar 17, 2022   
    P3,  N=1421, Active, not recruiting, 
    Inadvertent administration of the rotavirus vaccine in biologic-exposed infants did not result in more adverse events, raising the possibility of safety. Recruiting --> Active, not recruiting
  • ||||||||||  Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
    Trial completion date, Trial primary completion date:  SPLENEVAC-2: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. (clinicaltrials.gov) -  Mar 15, 2022   
    P2,  N=56, Recruiting, 
    Recruiting --> Completed Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Feb 2023 --> Jun 2023
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Journal:  Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections. (Pubmed Central) -  Mar 11, 2022   
    Initially, a 23-valent polysaccharide vaccines (PPSV) PNEUMOVAX®23, was developed to generate an antigen-specific immune response and prevent diseases caused by these pneumoniae serotypes...This SEC-UV-MALS-RI method is employed to characterize and monitor process intermediates and product during process development and for product release and stability testing. With this, we have expanded the multi-attribute SEC method to a 15-valent pneumococcal conjugate vaccine.